Results 21 to 30 of about 177 (68)

In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates [PDF]

Journal of Antimicrobial Chemotherapy, 2017
F901318 is a new antifungal agent with a novel mechanism of action with activity against Aspergillus species. We investigated the in vitro activity of F901318 against a collection of Aspergillus isolates.A total of 213 Aspergillus isolates were used in this study.
Buil, J.B., Rijs, A.J.M.M., Meis, J.F.G.M., Birch, M., Law, D., Melchers, W.J.G., Verweij, P.E.   +6 more
openaire   +4 more sources

In vitro activity of the novel antifungal compound F901318 against Australian Scedosporium and Lomentospora fungi [PDF]

Medical Mycology, 2018
We determined the in vitro activity of the novel orotomide antifungal, F901318, against 30 Lomentospora prolificans, 20 Scedosporium apiospermum, 7 S. aurantiacum, and 3 S. boydii, isolates in comparison with standard antifungals. Against L. prolificans, F901318 was the most potent compound (MIC90 0.25 μg/ml); the geometric mean MIC (0.26 μg/ml) was ...
Chayanika, Biswas, Derek, Law, Michael, Birch, Catriona, Halliday, Tania C, Sorrell, John, Rex, Monica, Slavin, Sharon C-A, Chen   +7 more
openaire   +2 more sources

In vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies

Journal of Antimicrobial Chemotherapy, 2019
To investigate the in vitro activity of olorofim (F901318), a novel broad-spectrum antifungal agent, against 150 strains belonging to 16 different cryptic species of Aspergillus by EUCAST and CLSI methodologies.Olorofim, amphotericin B, micafungin, posaconazole and voriconazole were tested against cryptic species belonging to Aspergillus fumigatus ...
Olga Rivero-Menendez, Manuel Cuenca-Estrella, Ana Alastruey-Izquierdo   +2 more
openaire   +2 more sources

The Significance of Mono‐ and Dual‐Effective Agents in the Development of New Antifungal Strategies

Chemical Biology &Drug Design, Volume 105, Issue 1, January 2025.
The future of treating challenging fungal infections lies in novel therapies targeting new antifungal targets, overcoming resistance mechanisms, and exploring innovative dual inhibitors. ABSTRACT Invasive fungal infections (IFIs) pose significant challenges in clinical settings, particularly due to their high morbidity and mortality rates.
Cengiz Zobi, Oztekin Algul
wiley   +1 more source

What is the role of microbial biotechnology and genetic engineering in medicine?

MicrobiologyOpen, Volume 13, Issue 2, April 2024.
Microbial biotechnology, the technological application of microorganisms, has been instrumental in producing significant natural bioactive products. These include antibiotics, antifungals, anticancer drugs, antiparasitics, antivirals, immunosuppressants, toxoid vaccines, and therapeutic enzymes.
Fernando Santos‐Beneit
wiley   +1 more source

Additional file 1 of Review of the novel antifungal drug olorofim (F901318)

Supplementary Material ...
Vanbiervliet, Yuri, Van Nieuwenhuyse, Tine, Aerts, Robina, Lagrou, Katrien, Spriet, Isabel, Maertens, Johan   +5 more
openaire   +1 more source

Additional file 2 of Review of the novel antifungal drug olorofim (F901318)

Supplementary Material ...
Vanbiervliet, Yuri, Van Nieuwenhuyse, Tine, Aerts, Robina, Lagrou, Katrien, Spriet, Isabel, Maertens, Johan   +5 more
openaire   +1 more source

Antifungal Agent F901318 [PDF]

, 2020
openaire   +1 more source

The Future of Antifungal Drug Therapy: Novel Compounds and Targets. [PDF]

Antimicrob Agents Chemother, 2021
Mota Fernandes C, Dasilva D, Haranahalli K, McCarthy JB, Mallamo J, Ojima I, Del Poeta M.   +6 more
europepmc   +1 more source

Recent drug development and treatments for fungal infections. [PDF]

Braz J Microbiol, 2023
Roy M, Karhana S, Shamsuzzaman M, Khan MA.   +3 more
europepmc   +1 more source